equal to V 10,695 while the outpatient events was equal to V 1,670. The 20% most expensive patients accounted for 63% of the total costs. CONCLUSIONS: Most PAH patients have multiple hospital events per year. While the number of inpatient events have remained stable per year, outpatient events have increased. Inpatient events are responsible for the majority of the economic burden.OBJECTIVES: To assess the annual economic burden of asthma in adults in Greece as well as the factors that may influence this burden. METHODS: A population-based, random-digit dialed, telephone nationwide survey was conducted to recruit patients with asthma in Greece (N¼353). A structured questionnaire was used to collect data regarding demographic and lifestyle characteristics, presence of comorbidities, disease history, asthma control during the past 4 weeks through the Asthma Control Test (ACT), healthcare resource utilization during the past 12 months, out-of-pocket expenses for reasons related to their asthma as well as productivity loss during the past 12 months. Direct health care cost that reflects and encapsulates all the resource consumption incurred for the care of patients within the health care system was calculated. Indirect cost that reflects productivity losses caused by patients' inability to work or because relatives need to take time off work to take care of them was also calculated. The total societal cost was calculated in V2017. RESULTS: The mean (95% CI) total annual cost per patient for asthma management from societal perspective was V895 (V620; V1015) with the direct and indirect cost accounting for almost 96% and 4% of the total cost, respectively. The total direct medical annual cost from societal perspective was mainly driven by the medication cost (48%), followed by the cost of laboratory and diagnostic tests (33%). The total annual costs from societal and payer perspective were found to be significantly higher in patients with not wellcontrolled asthma (ACT <20), in patients having had exacerbations and those with active symptoms of asthma during the previous 12 months. CONCLUSIONS: Our findings indicate that asthma control is strongly associated with the economic burden of asthma, demonstrating the need for the implementation of programs aiming at the management of chronic symptoms related to this condition.

paclitaxel or docetaxel, after adjuvant chemotherapy. For mBC, associations with docetaxel or paclitaxel were considered for first line and monotherapy for second. A survey was performed with 28 HMOs to map fees and sources used for reimbursement of drugs, materials and procedures. Resource use estimates were performed by a multidisciplinary team. Direct medical costs were included; drugs and material prices were obtained from published sources and fees from survey results. Time horizon was 5 years and market share considered the uptake of subcutaneous trastuzumab starting with 20% in the first year, increasing to 100% in the fifth year. A deterministic sensitivity analysis was conducted to analyze model robustness. RESULTS: In 5 years, 31,589 breast cancer patients were estimated for the private healthcare system, 284 patients for big, 30 patients for medium, and 6 patients for small HMOs. The progressive uptake of subcutaneous trastuzumab, compared with intravenous, can save up to 948,2 mBRL, 14,3 mBRL, 1,5 mBRL and 0,2 mBRL, respectively. Materials and support procedures along with medical fees were the most sensitive parameters. CONCLUSIONS: Compared with the intravenous administration, subcutaneous trastuzumab can save up to 948,2 mBRL costs on breast cancer treatment in the Private Healthcare System.